Lexeo Therapeutics, Inc. (LXEO) Regulatory Update And Interim Phase 1/2 Data Update For LX2006 For The Treatment Of Friedreich Ataxia Cardiomyopathy Call Transcript [Seeking Alpha]
Lexeo Therapeutics, Inc. (LXEO)
Company Research
Source: Seeking Alpha
Company Participants Louis Tamayo - CFO & Principal Accounting Officer R. Townsend - CEO & Director Sandi Tai - Chief Development Officer Eric Adler - Chief Medical Officer & Head of Research Conference Call Participants Tessa Romero - JPMorgan Chase & Co, Research Division Brian Skorney - Robert W. Baird & Co. Incorporated, Research Division Lili Nsongo - Leerink Partners LLC, Research Division Leland Gershell - Oppenheimer & Co. Inc., Research Division Mitchell Kapoor - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good morning, and welcome to the Lexeo Therapeutics webcast presentation on LX2006 for the treatment of Friedreich's ataxia cardiomyopathy. As a reminder, this call is being recorded today, October 7, 2025. I would now like to turn the conference over to Louis Tamayo, Chief Financial Officer of Lexeo Therapeutics. Louis, please go ahead. Louis Tamayo CFO & Principal Accounting Officer Earlier today, we released the r
Show less
Read more
Impact Snapshot
Event Time:
LXEO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LXEO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LXEO alerts
High impacting Lexeo Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LXEO
News
- Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) ForumGlobeNewswire
- Lexeo Therapeutics (NASDAQ:LXEO) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $19.00 price target on the stock.MarketBeat
- Lexeo Therapeutics (NASDAQ:LXEO) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $19.00 price target on the stock.MarketBeat
- Lexeo Therapeutics (NASDAQ:LXEO) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=LXEO&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreetMarketBeat
- Lexeo Therapeutics: Behind The Rebound [Seeking Alpha]Seeking Alpha
LXEO
Earnings
- 8/14/25 - Beat
LXEO
Sec Filings
- 11/28/25 - Form EFFECT
- 11/26/25 - Form 424B3
- 11/20/25 - Form 4
- LXEO's page on the SEC website